SecBot SecBot
SECBOTREPLAY Home › Report › PDSB

PDSB · PDS Biotechnology announced a strategic refocus prioritizing PDS0301 in…

PDS Biotechnology Corp · 8-K filed Aug 11, 2026 at 08:30 ET

At the news

BEARISHIMPACT 7/10

8-K filed Aug 11, 2026 at 08:30 ET

PDS Biotechnology announced a strategic refocus prioritizing PDS0301 in metastatic colorectal cancer (mCRC) and discontinuing internal investment in the PDS0101 Phase 3 VERSATILE-003 trial, seeking a partnership for PDS0101 instead. The company cited encouraging Phase 2 data for PDS0301, including a 71% ORR at 6 months and 80% 24-month survival in MSS/pMMR mCRC with liver metastases. This is a material pipeline restructuring that abandons the most advanced program (PDS0101 Phase 3) in favor of an earlier-stage asset, creating significant binary risk around PDS0301's upcoming Phase 2b data.

  • PDS Biotech is discontinuing the PDS0101 Phase 3 VERSATILE-003 trial and ceasing further internal investment in PDS0101.
  • The company is prioritizing PDS0301, an earlier-stage tumor-targeted immunocytokine, as its lead development program.
  • PDS0301 Phase 2 data in MSS/pMMR mCRC with liver metastases showed a 71% ORR at 6 months and an 80% 24-month survival rate.
  • PDS0301 has been evaluated in over 380 patients with an encouraging safety profile.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access